Phage therapy can be most simply understood as an alternative to antibiotics, especially in the context of bacterial infections that have developed resistance to conventional treatments. However, a more refined approach—based on the study of natural bacterial-phage equilibria—can help avoid common errors that may lead to therapeutic failure. This strategy distinguishes phage therapy from traditional pharmacological methods. In fact, both approaches can be effectively combined, including in compassionate use cases. After possible outbreak and equilibrium change a thorough understanding of the environmental conditions in which treatment is applied allows for more precise therapies, helping to achieve specific goals. The bacteria-to-phage (B/P) ratio is directly influenced by microbial variability and results from multifactorial interactions (Ref 1). These interactions determine whether a system is in a healthy or pathological state, influenced by internal or external factors. Introducing new phages into an existing microbial system does trigger changes, potentially reducing the B/P ratio (typically by increasing the phage population, i.e., the denominator). In vivo, using phage cocktails allows for targeting multiple bacterial species simultaneously, helping to reduce also the development of resistance. Therefore, information on microbiota composition and environmental conditions is essential to move toward a stable ecosystem, ideally mirroring a healthy state characterized by a positive B/P equilibrium. To achieve this, expanding our knowledge of unknown phage populations—the so-called "phage dark matter"—is critical (Ref 2). This would broaden the available phage repertoire and increase the chances of therapeutic success. Both in vitro and in vivo studies are needed (Ref 3) to track microbiota changes during phage therapy, particularly by monitoring metagenomic variations and infer microbial interactions. We present two examples that illustrate these concepts: 1) A metagenomic comparison of natural marine environments affected or not by long-term human activity. 2) An experimental study involving mice, comparing untreated microbiota to microbiota altered by DSS-induced colitis. These examples confirm the high variability in bacterial and phage populations under different environmental conditions. For instance, cyanobacteria and their associated phages (cyanophages of Myoviridae) are nearly absent in the Arctic Ocean but are highly abundant in the Persian Gulf. The mice gut microbiota analysis detected a diverse range of bacteria and phages. However, in DSS-treated mice, the B/P ratio decreased, with a significant increase in total phage counts. Specifically, Bacteroides became more abundant but with a lower phage ratio, while Clostridioides became less abundant, with their associated phages increasing. Increase of Caudovirales (bacteriophages) is associated with a decrease in enteric bacteria in inflammatory gut condition. Another important variable—prophage induction—was not measured in this study but should be considered in future research.

Frezza, D., Di Lallo, G., Brandtner, D., D’Addabbo, P., Mancini, P., Bosi, A., et al. (2025). METAGENOMIC STUDY TOWARDS PHAGE THERAPY INPROVEMENT: WHAT DO WE LEARN FROM BALANCE AND BACTERIA / PHAGE RATIO?. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? The 8th World Conference on Phage Therapy 2025, Berlino.

METAGENOMIC STUDY TOWARDS PHAGE THERAPY INPROVEMENT: WHAT DO WE LEARN FROM BALANCE AND BACTERIA / PHAGE RATIO?

FREZZA Domenico
Writing – Original Draft Preparation
;
Gustavo Di Lallo
Conceptualization
;
2025-01-01

Abstract

Phage therapy can be most simply understood as an alternative to antibiotics, especially in the context of bacterial infections that have developed resistance to conventional treatments. However, a more refined approach—based on the study of natural bacterial-phage equilibria—can help avoid common errors that may lead to therapeutic failure. This strategy distinguishes phage therapy from traditional pharmacological methods. In fact, both approaches can be effectively combined, including in compassionate use cases. After possible outbreak and equilibrium change a thorough understanding of the environmental conditions in which treatment is applied allows for more precise therapies, helping to achieve specific goals. The bacteria-to-phage (B/P) ratio is directly influenced by microbial variability and results from multifactorial interactions (Ref 1). These interactions determine whether a system is in a healthy or pathological state, influenced by internal or external factors. Introducing new phages into an existing microbial system does trigger changes, potentially reducing the B/P ratio (typically by increasing the phage population, i.e., the denominator). In vivo, using phage cocktails allows for targeting multiple bacterial species simultaneously, helping to reduce also the development of resistance. Therefore, information on microbiota composition and environmental conditions is essential to move toward a stable ecosystem, ideally mirroring a healthy state characterized by a positive B/P equilibrium. To achieve this, expanding our knowledge of unknown phage populations—the so-called "phage dark matter"—is critical (Ref 2). This would broaden the available phage repertoire and increase the chances of therapeutic success. Both in vitro and in vivo studies are needed (Ref 3) to track microbiota changes during phage therapy, particularly by monitoring metagenomic variations and infer microbial interactions. We present two examples that illustrate these concepts: 1) A metagenomic comparison of natural marine environments affected or not by long-term human activity. 2) An experimental study involving mice, comparing untreated microbiota to microbiota altered by DSS-induced colitis. These examples confirm the high variability in bacterial and phage populations under different environmental conditions. For instance, cyanobacteria and their associated phages (cyanophages of Myoviridae) are nearly absent in the Arctic Ocean but are highly abundant in the Persian Gulf. The mice gut microbiota analysis detected a diverse range of bacteria and phages. However, in DSS-treated mice, the B/P ratio decreased, with a significant increase in total phage counts. Specifically, Bacteroides became more abundant but with a lower phage ratio, while Clostridioides became less abundant, with their associated phages increasing. Increase of Caudovirales (bacteriophages) is associated with a decrease in enteric bacteria in inflammatory gut condition. Another important variable—prophage induction—was not measured in this study but should be considered in future research.
The 8th World Conference on Phage Therapy 2025
Berlino
2025
Marvin Edeas
Rilevanza internazionale
su invito
11-giu-2025
2025
Settore BIOS-15/A - Microbiologia
English
Intervento a convegno
Frezza, D., Di Lallo, G., Brandtner, D., D’Addabbo, P., Mancini, P., Bosi, A., et al. (2025). METAGENOMIC STUDY TOWARDS PHAGE THERAPY INPROVEMENT: WHAT DO WE LEARN FROM BALANCE AND BACTERIA / PHAGE RATIO?. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? The 8th World Conference on Phage Therapy 2025, Berlino.
Frezza, D; Di Lallo, G; Brandtner, D; D’Addabbo, P; Mancini, P; Bosi, A; Giaroni, C; Baj, A; Malinverni, R; Sanseverino, W; Iaconelli, M; Giuseppina L...espandi
File in questo prodotto:
File Dimensione Formato  
11-6-25 FREZZA Berlin PT.pdf

accesso aperto

Tipologia: Altro materiale allegato
Licenza: Non specificato
Dimensione 58.39 kB
Formato Adobe PDF
58.39 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/439063
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact